Mabion ma wolne moce produkcyjne w najnowcześniejszej technologi na świecie.Jaki konkrekt dla MAB z tego wynika poza listem?Muszę koledze pogratulować trafności oceny sytuacji.
cytat z politico który wspomina kolega powyżej:
Amid alarming spikes in infections and a wave of new restrictions announced across Europe, some good news is emerging: Monoclonal antibodies are likely to be the first game-changing therapy against COVID-19.
Jak sie to ma do Mabionu:
List intencyjny podpisany z IcanoMAB właśnie dotyczy tego rozwiązania.(ciał monoklonalnych)
No dobrze ale co to jest IcanoMab, firma która powstała zaledwie miesiąc temu !.
Grzebiąc w internecie znalazłem następujace informacje:
IcanoMAB was founded by highly experienced entrepreneurs and scientists with a track record of successful drug development in multiple companies including Boehringer Mannheim, Roche, MAB Discovery, Xantos Biomedicine, JSB Partners, Novartis and TVM Capital Life Science. The company was founded by MAB Discovery, represented by Dr. Stephan Fischer, its CEO, Dr. Ulrich Pessara and Daniel Parera, M.D..
No dobrze ale co to jest Mab Discovery:
About MAB Discovery
Founded in 2010 by Dr. Stephan Fischer, MAB Discovery utilizes a unique and proprietary rabbit-based antibody discovery platform to generate and develop high quality, functional monoclonal antibodies targeting traditional proteins and receptors as well as a wide variety of more challenging immunogens such as GPCRs and ion channels. The MAB Discovery team has extensive experience in developing antibody-based therapeutics having worked together at Roche Biologicals for several years. In recent years, MABD used its proprietary platform to generate various mAbs for several pharma partners and for the generation of proprietary mAbs focusing on highly attractive targets with proven therapeutic relevance.
Co sie stało z Mab Discovery.
szukamy dalej;
January 23, 2019
MAINZ, Germany & MUNICH--(BUSINESS WIRE)--BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB Discovery GmbH, a unique player in the generation and development of sophisticated and therapeutically relevant monoclonal antibodies (mAbs), today announced that both partners have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.
No dobrze ale co to jest BioNTech:
About BioNTech
BioNTech is Europe’s largest privately-held biopharmaceutical company pioneering the development of more precise and individualized therapies for cancer and the prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s commercial approach is validated by seven corporate partnerships with Genentech, a member of the Roche Group, Pfizer, Genmab, Eli Lilly and Company, Sanofi, Genevant and Bayer Animal Health and its scientific approach through over 60 peer-reviewed scientific publications, including five publications in Nature. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. For more information, please see: www.biontech.de
Biontech będzie prawdopodnie pierwszą firma która razem z Pfizerem wprowadzi nową szczepionkę na COVID na cały świat.
Co takiego jest fajnego w IcanoMAB:
proszę bardzo:
IcanoMAB has secured three clinical candidates in IND-enabling stage and funding from MAB Discovery GmbH, originally generating the licensed antibodies from a novel antibody discovery platform. IcanoMAB will use its proceeds to advance the clinical candidates to allow IND-enabling activities and respective partnering activities with selected third parties.
3 przeciwciała IcanoMAB to:
- HER2newC Apoptosis Inducer – Early Breast Cancer
- CD40 Agonist – Immuno-Oncology/Severe Infectious Diseases
- IL-1R7 Antagonist – Acute Inflammatory Diseases -faza-gotowy do badań klinicznych
IL-1R7 to lek na:
effective treatments are particularly urgent for Covid-19 and its potentially fatal outcome driven by Acute Respiratory Distress Syndrome (ARDS) and subsequent Cytokine Release Syndrome (CRS). While Vaccine development is progressing and sufficient broad population protection is yet to be demonstrated, risks of detrimental effects via Antibody Dependent Enhancement (ADE) will require specific therapeutic intervention. In any case, an effective treatment is urgently needed as an option for clinicians to treat severely affected late-stage Covid-19 patients. Significant improvement of clinical outcome is also required for the treatment of disorders in immunology and inflammation including several severe rare diseases like macrophage-activation syndrome, SJIA / Still’s Disease or IBD and Gout where sometimes even specific treatments are missing, that address the underlying cause.
Mabion podpisał list intencyjny dotyczący IL-1R7
Jak myślicie dlaczego tak firma jak IcanoMAB, która powstała specjalnie po to aby wprowadzić na wielomiliardowy rynek nowatorski lek na COVID-19 podpisała list intencyjny z takim bankrutującym Mabionem ?
Proszę zastanówmy się razem o co tu może chodzić ?
Moim zdaniem sprawa z VAXINE to przy tym pikuś.
Największy na świecie orbital shaker 2500 l Kuchnera został specjalnie zaprojektowany dla Mabionu.
Mabion ma już 2 bioreaktory i może dostawić szybko 2 następne.
Jeżeli lek z IcanoMab lub inny wypali to w ciągu 2 lat rozbudowują fabrykę o następne 12x2500l.(wszytkie projekty i pozwolenia już mają)
40000 litrów to już całkiem spora fabryka biotech.
Ktoś to musi wykorzystać- np. IcanMab
